Sermorelin Dosage in the Research Literature

Sermorelin has a plasma half-life of approximately 11-12 minutes after either intravenous or subcutaneous administration [4]. Peak serum concentration is reached in 5-20 minutes after subcutaneous injection [4]. Mean absolute subcutaneous bioavailability: approximately 6% [4]. Mean plasma clearance: 2.4-2.8 L/min in adults [4]. Volume of distribution: 23.7-25.8 L after IV dosing [4].

The short half-life is a consequence of rapid proteolytic clearance by serum DPP-4 and other serum proteases. The GH pulse that sermorelin triggers continues for 2-4 hours after the peptide itself is cleared from circulation [4]. This decoupling — short peptide half-life, extended GH response — is the pharmacokinetic basis for the pre-sleep dosing rationale: the peptide acts in the first 20 minutes, the GH response it initiates runs through the first half of the sleep period.

Comparison: CJC-1295 without DAC has a half-life of approximately 30 minutes (DPP-4-resistant amino acid substitutions); CJC-1295 with DAC achieves 6-8 day half-life via albumin binding [19]. Tesamorelin (FDA-approved GHRH analog for HIV-associated lipodystrophy) achieves greater stability via a trans-3-hexenoic acid modification without the sustained-release pharmacokinetics of CJC-1295 DAC [13].

Sermorelin is susceptible to degradation in solution; reconstituted preparations require refrigeration and protection from light per prescribing literature [4].

Human clinical studies found statistically significant GH elevations at doses as low as 30 mcg/kg during diagnostic stimulation studies in adults [4]. Dose-response curves show diminishing GH increments above approximately 1 mg/dose, attributable to receptor saturation and somatostatin feedback [4].

In the Geref pediatric therapeutic program, 30 mcg/kg once daily produced strong efficacy: height velocity doubled from 4.1 to 8.0 cm/year at six months [1]. The adult retrospective compound pharmacy literature uses a different weight-independent dosing convention: typically 200-300 mcg once daily subcutaneous, which reflects the practical dosing window studied in adult cohort analyses [4].

The adult 100-300 mcg range is supported indirectly by the Sigalos 2017 study of GH secretagogue treatment in 14 hypogonadal men at 100 mcg three times daily — a higher total daily dose that produced statistically significant IGF-1 elevation (p<0.0001) [3].

High ambient free fatty acids reduce GH response to GHRH analogs via pituitary-level autofeedback [10]. Elevated exogenous GH and glucocorticoids also blunt the GH response to GHRH stimulation [10].

Clinical protocols administered sermorelin at bedtime to align with the endogenous nocturnal GH surge [6][8]. The rationale: approximately 70% of nocturnal GH secretion aligns with SWS stages, and the largest GH pulse occurs shortly after sleep onset [6]. Sleep onset — not SWS stage per se — is the anchor: when sleep onset was delayed to 02:00 in experimental subjects, GH secretory bursts also shifted, aligning with the new post-sleep-onset SWS [8].

Nocturnal GHRH administration during the first half of the night increased both GH plasma levels and SWS; morning administration (04:00-07:00) raised GH without altering sleep [7]. The pre-sleep timing window is designed to augment the natural nocturnal pulse rather than introduce an out-of-phase GH stimulus.

The 11-12 minute half-life means sermorelin clears before most subjects fall asleep; the GH pulse it triggers then unfolds during early sleep. The alignment is precise by design.

Subcutaneous injection is the standard therapeutic and research route [2][15]. The prescribing literature specifies rotation of injection sites to avoid lipodystrophy. Common sites in clinical protocols: abdominal adipose tissue, upper arm, thigh.

IV administration was used for diagnostic stimulation testing (1 mcg/kg single IV dose) and pharmacokinetic studies, not for therapeutic protocols [2][4].

Intranasal administration has been investigated as a non-invasive alternative; bioavailability via this route is substantially lower than subcutaneous [4]. It has not been validated in randomized therapeutic trials.

Injection site reactions (pain, swelling, redness) occurred in approximately 16% of patients across the 350-patient Geref clinical trial pool [15]. Three patients discontinued. These are the most common documented adverse events; systemic adverse events had individual occurrence rates below 1% each [15].

Week-by-week outcome data from the research literature suggest the following sequence.

Weeks 2-4: IGF-1 elevation and early subjective outcomes (sleep quality changes) are the earliest documented signals. The Sigalos 2017 adult male GH secretagogue study showed measurable IGF-1 changes within the first monitoring window (approximately 30 days) [3].

Weeks 6-8: Statistically significant IGF-1 elevations are confirmed in clinical studies [3]. The pediatric height velocity data shows meaningful improvement by the first six-month assessment [1].

Months 3-6: Body composition outcomes (lean mass increase, fat mass reduction) require this duration to become measurable in clinical trials. The tesamorelin GHRH-class RCTs document significant body composition changes over this window [13].

Year 1-2: Sustained GH pulse restoration and cumulative body composition outcomes are documented in the two-year GH secretagogue RCTs [11][16]. Bone density improvements accrue over this period as well [14].

Three months of sermorelin: the 3-month window shows early IGF-1 increases and sleep quality changes, but the clinical studies examining body composition and bone density outcomes used 6-24 month durations. Three months is insufficient to assess body composition endpoints in the trial literature [1].

GH response to GHRH analogs is modulated by metabolic state at the time of administration. The key variable: circulating free fatty acids (FFA).

Elevated FFA blunts GH response to GHRH stimulation via a pituitary-level autoinhibitory mechanism — distinct from and additive to somatostatin feedback [10]. In a controlled human study, methionyl-GH infusion inhibited GH response to GHRH stimulation even when peripheral lipolysis and hypothalamic somatostatin were pharmacologically blocked [10].

The implication for dosing timing: fasted-state administration and low-carbohydrate conditions, which lower circulating FFA, are associated with higher GH pulse amplitudes in controlled settings. Post-meal states with elevated FFAs from lipolysis of dietary fat reduce the GHRH-stimulus GH response [10].

Glucocorticoids and high exogenous GH levels reduce GHRH analog efficacy through separate feedback pathways [10].

Human clinical trials studying sermorelin administered it for 6-24 months in the efficacy-focused studies [1][2]. The three-month window captures early IGF-1 elevation but falls short of the duration used to assess body composition and bone density endpoints in the research record.

The two-year ibutamoren GH secretagogue RCT (65 healthy adults) sustained pulsatile GH restoration and fat-free mass improvements for the full study period without evidence of tachyphylaxis [11]. The tesamorelin RCTs (five studies, meta-analysis) documented effects over periods consistent with sustained dosing [13].

Long-term sermorelin use: the pediatric Geref program found no pituitary hyperplasia and no antibody-mediated efficacy loss across multi-year follow-up [2]. Adult long-term data are limited. See long-term safety data on the research page for the full discussion.